Anesthesia and Sedation
AQUAVAN® Injection is a novel, water-soluble pro-drug of propofol that is rapidly converted in the body into propofol after intravenous administration and may offer advantages over traditional anesthetic agents.
In 2002, Guilford commenced two Phase II studies of AQUAVAN® Injection. The first study is a Phase II study, being conducted in Europe, in patients undergoing coronary artery bypass surgery. The second Phase II study, taking place in the U.S., is a 200 patient clinical trial evaluating the use of AQUAVAN® Injection for use in conscious sedation in patients undergoing colonoscopy procedures.
Propofol is an intravenous drug widely used to anesthetize or sedate patients undergoing surgery or other diagnostic or medical procedures. Despite its commercial success, propofol has been associated with various side effects that include: cardiovascular side effects (such as reduced heart rate and decreased blood pressure), depressed respiration, elevated blood lipid levels, pain at the site of injection, and a potential for bacterial contamination that could lead to infection.
Guilford believes AQUAVAN® Injection may have significant advantages over currently marketed sedative/hypnotic agents, including, the potential for enhanced safety, more convenient dosing, and a reduced hang over effect. The effects are currently being evaluated in two ongoing Phase II clinical studies of AQUAVAN® Injection, which should be completed in late 2003.
This page was last updated on
Copyright© 2001 Guilford Pharmaceuticals Inc.